News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Alex Bataller: Phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML
Photo of Alex Bataller/LinkedIn
Feb 15, 2024, 18:42

Alex Bataller: Phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML

Alex Bataller, Leukemia fellow at Leukemia Department, MD Anderson Cancer Center (Houston, Texas), shared a post on X/Twitter:

”Delighted to announce our newest publication in The Lancet Haematology of the phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML.

This totally oral combination had an acceptable toxicity profile with an encouraging ORR of 95% and 49% of patients undergoing subsequent HSCT.”

Alex Bataller: Phase 1/2 trial results of oral decitabine/cedazuridine with venetoclax in higher risk MDS and CMML

Source: Alex Bataller/X

Alex Bataller cancer MDS and CMML OncoDaily Oncology oral decitabine/cedazuridine with venetoclax The Lancet Haematology Toxicity Profile
Special Coverage
Science
Jan 19, 2025, 07:52
Paolo Tarantino: What’s distinct about Breast cancers with ERBB2?
Science
Jan 19, 2025, 07:45
Cristiane Bergerot: Mindfulness via smartphone
Science
Jan 19, 2025, 07:42
Xiuning Le: The number of newly diagnosed female lung cancer cases has surpassed that of males
Insight
Jan 19, 2025, 07:37
Stephanie Graff: Excited to have another therapeutic option to treat advanced HR+ breast cancer
Dialogues
Jan 19, 2025, 07:33
The Experience of Colorectal Cancer Screening in Kazakhstan
Science
Jan 19, 2025, 07:29
Melissa Loh: Protocol paper on our multicenter UR-GOAL study
Science
Jan 19, 2025, 07:26
Emre Yekedüz: Happy to share our studies at ASCO GU25
Science
Jan 19, 2025, 07:23
The incidence of GEP-NETs in the US
Science
Jan 19, 2025, 07:17
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer
Science
Jan 19, 2025, 07:02
Erman Akkus: Understanding the BRAF pathway
Science
Jan 19, 2025, 06:59
Paolo Tarantino: A new ADC is now available to treat the most common subtype of breast cancer
Science
Jan 19, 2025, 06:56
Pashtoon Kasi: One more option for our patients with Colorectal Cancer